Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388169 | 0.81 | CYP2A6 (0.42) | CYP2A6ADRB2ASIC3LOXL2MGLL | |
| SCHEMBL820486 | 0.79 | MGLL (0.50) | CYP2A6ADRB2ASIC3LOXL2MGLL | |
| SCHEMBL12470420 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL354292 | 0.78 | CYP2A6 (0.48) | CYP2A6ADRB2ASIC3LOXL2MGLL | |
| SCHEMBL11893293 | 0.77 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2MGLL | |
| SCHEMBL2387149 | 0.76 | MGLL (0.47) | CYP2A6ADRB2ASIC3LOXL2MGLL | |
| SCHEMBL16009726 | 0.76 | MGLL (0.52) | CYP2A6ADRB2ASIC3LOXL2MGLL | |
| SCHEMBL30099136 | 0.75 | CYP2A6 (0.45) | CYP2A6ADRB2ASIC3LOXL2MGLL | |
| SCHEMBL1765981 | 0.75 | CYP2A6 (0.45) | CYP2A6ADRB2ASIC3LOXL2MGLL | |
| SCHEMBL28019294 | 0.74 | MGLL (0.50) | CYP2A6ADRB2ASIC3LOXL2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059951-A1 | INHIBITORS OF THE ANDROGEN RECEPTOR DNA-BINDING DOMAIN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-03-28 | — | — | WO | disclosed |
| CN-105992808-B | Use of magnetic nanoparticles for depleting aromatic compounds in oil | 综合E&P丹麦股份有限公司 | 2018-10-19 | — | — | CN | disclosed |
| US-9969943-B2 | Use of magnetic nanoparticles for depletion of aromatic compounds in oil | MAERSK OLIE OG GAS A/S (DK) | 2018-05-15 | — | — | US | disclosed |
| US-9708323-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160272898-A1 | USE OF MAGNETIC NANOPARTICLES FOR DEPLETION OF AROMATIC COMPOUNDS IN OIL | TOTAL E&P DANMARK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| WO-2015044449-A1 | USE OF MAGNETIC NANOPARTICLES FOR DEPLETION OF AROMATIC COMPOUNDS IN OIL | MÆRSK OLIE OG GAS A/S (DK) | 2015-04-02 | — | — | WO | disclosed |
| US-8329718-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8021540-B2 | Method of desulfurizing hydrocarbon oil | JAPAN ENERGY CORPORATION (JP) | 2011-09-20 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100227229-A1 | SOLID ACID, METHOD FOR PREPARING THE SOLID ACID, AND METHOD FOR DESULFURIZING HYDROCARBON OIL USING THE SOILD ACID AS DESULFURIZING AGENT | JAPAN ENERGY CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2202204-A1 | SOLID ACID, PROCESS FOR PRODUCING THE SOLID ACID, METHOD FOR DESULFURIZING HYDROCARBON OIL USING SOLID ACID AS DESULFURIZING AGENT | Japan Energy Corporation (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20100155303-A1 | METHOD FOR DESULFURIZATION OF HYDROCARBON OIL | JAPAN ENERGY CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. | 2010-06-10 | — | — | US | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090000990-A1 | Method of Desulfurizing Hydrocarbon Oil | JAPAN ENERGY CORPORATION (JP) | 2009-01-01 | — | — | US | disclosed |
| EP-1923451-A1 | METHOD FOR DESULFURIZATION OF HYDROCARBON OIL | JAPAN ENERGY CORPORATION (JP) | 2008-05-21 | — | — | EP | disclosed |
| CN-1914298-A | Method of desulfurizing hydrocarbon oil | JAPAN ENERGY CORP (JP) | 2007-02-14 | — | — | CN | disclosed |
| EP-1715025-A1 | METHOD OF DESULFURIZING HYDROCARBON OIL | JAPAN ENERGY CORPORATION (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | CYP2A6 3338/4885ADRB2 4652/4885ASIC3 4215/4885 |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | TMPRSS15, PRSS1, SPINT2 | CYP2A6 678/4885ADRB2 4742/4885ASIC3 3429/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | CYP2A6 2606/4885ADRB2 4513/4885ASIC3 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.